AB Science S.A

(PINK:ABSCF)

Latest On AB Science S.A (ABSCF):

Date/Time Type Description Signal Details
2022-08-24 15:25 ESTNewsAB Science's ALS drug Alsitek gets EMA reviewN/A
2021-07-22 16:25 ESTNewsAB Science's masitinib extends survival in ALS significantly; shares rise 7%N/A
2021-04-30 03:54 ESTNewsAB Science's masitinib meets primary endpoint in prostate cancer studyN/A
2021-04-07 09:05 ESTNewsAB Science licenses masitinib, other drugs to U of Chicago as potential COVID-19 therapiesN/A
2020-12-26 02:09 ESTNewsAB Science's Masitinib: An Uncertain Success For Alzheimer's DiseaseN/A
2020-12-18 23:52 ESTNewsAB Science is rising after positive data from Alzheimer’s trialN/A
2020-12-04 19:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-10-08 20:41 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:09 ESTFinancialsCompany financials have been released.Neutral
2020-10-03 03:45 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:23 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:03 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 16:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 19:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 11:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 04:12 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 20:23 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 08:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 00:32 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 16:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 23:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 16:07 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 20:55 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 12:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 07:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-02 23:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 19:56 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 03:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-25 07:10 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 15:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 08:01 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-06-07 19:34 ESTFinancialsCompany financials have been released.Neutral
2020-06-05 15:18 ESTFinancialsCompany financials have been released.Neutral
2020-06-03 19:11 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 08:36 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 04:22 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 03:38 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 09:00 ESTFinancialsCompany financials have been released.Neutral
2020-05-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 23:29 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 19:47 ESTFinancialsCompany financials have been released.Neutral
2020-04-30 07:16 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 11:02 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 07:11 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 03:26 ESTFinancialsCompany financials have been released.Neutral

About AB Science S.A (ABSCF):

AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

See Advanced Chart

General

  • Name AB Science S.A
  • Symbol ABSCF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 93
  • Fiscal Year EndDecember
  • Web URLhttp://www.ab-science.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 399.93
  • Enterprise Value Revenue 527.69
View More

Financials

  • Most Recent Quarter 2020-06-30
  • Return on Assets -42%
  • Earnings Per Share -$0.79
  • Revenue Per Share $0
  • Gross Profit 1.39 million
  • Quarterly Earnings Growth 2%
View More

Highlights

  • Market Capitalization 823.46 million
  • Book Value Per Share -$0.01
View More

Share Statistics

  • Shares Outstanding 44.35 million
  • Shares Float 28.56 million
  • % Held by Insiders 4361%
  • % Held by Institutions 5.03%
View More

Technicals

  • Beta 1.05
  • 52 Week High $26.7
  • 52 Week Low $6.9
  • 50 Day Moving Average 19.35
  • 200 Day Moving Average 19.75
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AB Science S.A (ABSCF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AB Science S.A (ABSCF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-03-312020-06-30$N/A-$0.13$0.00
2019-12-312020-03-31$N/A-$0.13$0.00
2019-09-302019-12-31$N/A-$0.12$0.00
2019-06-302019-09-30$395500-$0.12$0.00
2019-03-312019-06-30$395500-$0.19$0.00
2018-12-312019-03-31$414500-$0.19$0.00
2018-09-302018-12-31$414500-$0.23$0.00
2018-06-302018-09-30$436000-$0.23$0.00
2018-03-312018-06-30$436000-$0.17$0.00
2017-12-312018-03-31$448500-$0.18$0.00
2017-09-302017-12-31$448500-$0.23$0.00
2017-06-302017-09-30$421000-$0.23$0.00
2017-03-312017-06-30$421000-$0.21$0.00
2016-12-312017-03-31-$0.20$0.00
2016-09-302016-12-31-$0.19$0.00
2016-06-302016-09-30-$0.20$0.00
2016-03-312016-06-30-$0.23$0.00
2015-12-312016-03-31-$0.24$0.00
2015-09-302015-12-31-$0.21$0.00
2015-06-302015-09-30-$0.22$0.00
2015-03-312015-06-30-$0.22$0.00
2014-12-312015-03-31-$0.21$0.00
2014-09-302014-12-31-$0.16$0.00
2014-06-302014-09-30-$0.17$0.00
2014-03-312014-06-30-$0.15$0.00
2013-12-312014-03-31-$0.15$0.00
2013-09-302013-12-31-$0.17$0.00
2013-06-302013-09-30-$0.17$0.00
2013-03-312013-06-30-$0.13$0.00
2012-12-312013-03-31-$0.13$0.00
2012-09-302012-12-31-$0.11$0.00
2012-06-302012-09-30-$0.10$0.00
2012-03-312012-06-30-$0.12$0.00
2011-12-312012-03-31-$0.12$0.00
2011-09-302011-12-31-$0.10$0.00
2011-06-302011-09-30-$0.10$0.00
2011-03-312011-06-30-$0.12$0.00
2010-12-312011-03-31-$0.11$0.00
2010-09-302010-12-31-$0.10$0.00

AB Science S.A (ABSCF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AB Science S.A (ABSCF) Chart:

AB Science S.A (ABSCF) News:

Below you will find a list of latest news for AB Science S.A (ABSCF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AB Science S.A (ABSCF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

AB Science S.A (ABSCF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link